Ilana Schlam, Breast Medical Oncologist and Assistant Professor of Medicine at Tufts University Medical Center, shared a post on X:
“Updated treatment algorithms for breast cancer now include adjuvant ribociclib and inavolisib, along with trial names.
Thrilled to see we’re truly running out of space in HR+ disease—progress is here, with much more to come for all breast cancer subtypes.”
Ilana Schlam, MD, is a breast medical oncologist and Assistant Professor of Medicine at Tufts University Medical Center. Her research focuses on precision medicine, drug development, and addressing healthcare disparities in breast cancer treatment and outcomes.
